Artemis Therapeutics Inc.
ATMS · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -14.6% | 19.1% | 49.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.9% | 93.7% | 83.2% | 75% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $1 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -86.9% | -132.5% | -152.6% | -425.9% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | $0 | $0 | -$0 | -$1 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | $0 | $0 | -$0 | -$1 |
| % Margin | 0% | 7.3% | -135.3% | -446.6% |
| EPS | 0 | 0 | -0.002 | -0.091 |
| % Growth | -100% | 100% | 97.7% | – |
| EPS Diluted | 0 | 0 | -0.002 | -0.091 |
| Weighted Avg Shares Out | 112,034 | 112,034 | 112 | 6 |
| Weighted Avg Shares Out Dil | 112,034 | 112,034 | 112 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | -$0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | -$0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -86.9% | -132.5% | -150.3% | -422.4% |